UBS Group’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-291,457
| Closed | -$11.9M | – | 9104 |
|
|
2024
Q2 | $11.9M | Sell |
291,457
-14,084
| -5% | -$576K | ﹤0.01% | 1511 |
|
|
2024
Q1 | $12.9M | Buy |
305,541
+87,421
| +40% | +$3.7M | ﹤0.01% | 1449 |
|
|
2023
Q4 | $9.25M | Buy |
218,120
+90,463
| +71% | +$3.84M | ﹤0.01% | 1514 |
|
|
2023
Q3 | $2.79M | Buy |
127,657
+26,599
| +26% | +$581K | ﹤0.01% | 2290 |
|
|
2023
Q2 | $3.21M | Sell |
101,058
-21,917
| -18% | -$697K | ﹤0.01% | 2270 |
|
|
2023
Q1 | $3M | Buy |
122,975
+8,537
| +7% | +$208K | ﹤0.01% | 2239 |
|
|
2022
Q4 | $3.61M | Buy |
114,438
+95,357
| +500% | +$3.01M | ﹤0.01% | 2094 |
|
|
2022
Q3 | $539K | Sell |
19,081
-33,343
| -64% | -$942K | ﹤0.01% | 3309 |
|
|
2022
Q2 | $1.39M | Buy |
52,424
+15,529
| +42% | +$411K | ﹤0.01% | 2630 |
|
|
2022
Q1 | $1.29M | Sell |
36,895
-174,487
| -83% | -$6.11M | ﹤0.01% | 3019 |
|
|
2021
Q4 | $6.85M | Buy |
211,382
+203,162
| +2,472% | +$6.59M | ﹤0.01% | 1835 |
|
|
2021
Q3 | $243K | Buy |
8,220
+1,720
| +26% | +$50.8K | ﹤0.01% | 4150 |
|
|
2021
Q2 | $167K | Sell |
6,500
-1,903
| -23% | -$48.9K | ﹤0.01% | 4470 |
|
|
2021
Q1 | $115K | Sell |
8,403
-4,969
| -37% | -$68K | ﹤0.01% | 4879 |
|
|
2020
Q4 | $222K | Buy |
+13,372
| New | +$222K | ﹤0.01% | 4215 |
|